Travere Therapeutics Inc
(TVTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 54,116 | 41,374 | 45,059 | 37,095 | 32,196 |
| Cost of Goods | 2,061 | 1,504 | 4,564 | 1,289 | 1,452 |
| Gross Profit | 52,055 | 39,870 | 40,495 | 35,806 | 30,744 |
| Operating Expenses | 119,820 | 179,611 | 135,292 | 128,680 | 135,147 |
| Operating Income | -67,704 | -139,237 | -94,233 | -92,585 | -103,951 |
| Interest Expense | 2,788 | 2,800 | 2,820 | 2,821 | 2,843 |
| Other Income | 925 | 6,270 | 8,525 | 6,177 | 4,927 |
| Pre-tax Income | -69,567 | -135,767 | -88,528 | -89,229 | -101,867 |
| Income Tax | 85 | 191 | 68 | 12 | 65 |
| Net Income Continuous | -69,652 | -135,958 | -88,596 | -89,241 | -101,932 |
| Net Income Discontinuous | -757 | -103 | -1,577 | 239,976 | 16,302 |
| Net Income | $-70,409 | $-136,061 | $-90,173 | $150,735 | $-85,630 |
| EPS Basic Total Ops | -0.91 | -1.76 | -1.07 | 1.97 | -1.13 |
| EPS Basic Continuous Ops | -0.90 | -1.76 | -1.14 | -1.17 | -1.34 |
| EPS Basic Discontinuous Ops | -0.01 | 0.00 | 0.07 | 3.14 | 0.21 |
| EPS Diluted Total Ops | -0.91 | -1.76 | -1.07 | 1.97 | -1.13 |
| EPS Diluted Continuous Ops | -0.90 | -1.76 | -1.14 | -1.17 | -1.34 |
| EPS Diluted Discontinuous Ops | -0.01 | 0.00 | 0.07 | 3.14 | 0.21 |
| EPS Diluted Before Non-Recurring Items | -0.90 | -1.76 | -1.16 | N/A | N/A |
| EBITDA(a) | $-57,359 | $-129,357 | $-90,483 | $-81,110 | $-93,004 |